<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608215</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01-005B</org_study_id>
    <nct_id>NCT03608215</nct_id>
  </id_info>
  <brief_title>Neuromodulatary Efficacy of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea</brief_title>
  <official_title>Neuromodulation Effect of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea: BDNF and MEG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Dysmenorrhea (PDM), defined as menstrual pain without discernable organic causes, is
      inexorably common in adolescent women, about 40-90% of women may suffer from it, and 20% of
      them can be severe in the context of being refractory to medication, daily function
      impairment, and having pain of severe degree. Novel therapeutic method is in need for pain
      alleviation for this particular phenotype. It has been reported that PDM females may engage
      motor-cortex based descending pain modulation system in our resting-state functional Magnetic
      Resonance Imaging (rs-fMRI) and thermal pain-activation fMRI studies. Based on the reported
      analgesic efficacy of transcranial Direct Current Stimulation (tDCS) on the motor cortex for
      various experimental painful conditions and clinical pain disorders, it is plausible that
      tDCS can be effective for the severe and medication-refractory PDM patients. This study aim
      to investigate the analgesic efficacy of tDCS in severe PDMs and to elucidate the dynamic
      brain neuroplasticity in the context of experimental pain after tDCS intervention. Thirty
      severe PDMs will be recruited and randomly allocated to either real or sham group in a
      triple-blind manner. Experimental pain electrical stimulation will be performed before and
      after the tDCS intervention. The experimental pain-evoked magnetoencephamographic (MEG) data
      will be correlated with behavioral and psychological measurements. This is the first study in
      the literature investigating the tDCS efficacy for acute pain in severe PDM. The result can
      promise a new possibility for clinical application.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2015</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>active, sham</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>change from baseline (1st menstrual phase, before tDCS) at one month (2nd menstrual phase, with tDCS), change from baseline (1st menstrual phase, before tDCS) at two months (3rd menstrual phase)</time_frame>
    <description>pain scale; from 0 to 10; score 0: no pain, score 10: unbearable pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Somatosensory evoked magnetic fields to experimental pain</measure>
    <time_frame>change from baseline (before tDCS, before 2nd menstrual phase) at one week (after tDCS completion), change from baseline (before tDCS, before 2nd menstrual phase) at four weeks (before the 3rd menstrual phase)</time_frame>
    <description>Somatosensory evoked magnetic fields (SEFs) is a well established magnetoencephalographic (MEG) cortical response evoked by electric stimulation. SEFs to experimental pain stimulation using electrical stimulator applied on the skin over the trajectory of median nerve will be used to evaluate pain-evoked cortical response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative sensory testing (QST)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess the threshold of thermal sensation (cold, cold-pain, heat, heat-pain; from 0 to 50 centigrade temperature), according to the established protocol of an ascending limit approach for heat pain and a descending limit approach for cold pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spielberger State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess anxious symptoms; from 20 to 80; score 20: not anxious, score 80: extremely anxious</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess anxious symptoms; from 0 to 63; score 0: not anxious, score 63: extremely anxious</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess depressive symptoms; from 0 to 63; score 0: not depressed, score 63: extremely depressed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess pain-maladaptive psychological status; from 0 to 52; score 0: not pain Catastrophizing , score 52: extremely pain Catastrophizing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-form McGill Pain Questionnaire (MPQ)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess pain status; from 0 to 78; score 0: not painful, score 78: extremely painful</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey (SF-36)</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at five weeks (after the 3rd menstrual phase)</time_frame>
    <description>To assess quality of life; he SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. From 0 to 100; score 0: equivalent to maximum disability, score 100: no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Hormones Measurement</measure>
    <time_frame>change from baseline (before tDCS) at one week (after tDCS completion), change from baseline (before tDCS) at four weeks (before the 3rd menstrual phase)</time_frame>
    <description>To assess testosterone, progesterone, estrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping</measure>
    <time_frame>baseline</time_frame>
    <description>To genotype the single nucleotide polymorphism genotyping (i.e., BDNF Val66Met polymorphism (rs6265), COMT Val158Met polymorphism (rs4680), OPRM1 (rs1799971), 5HTR2A (rs6313), SLC6A4 (rs25531)) from blood specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of tDCS blinding</measure>
    <time_frame>At 1 months after tDCS intervention</time_frame>
    <description>To assure blinding efficacy; Patients do self-assessment about whether they receive real tDCS or sham tDCS. Assessment questionnaire:1 or 0. 1: real tDCS; 0: sham tDCS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Primary Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.</description>
    <arm_group_label>Active tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-35 years old PDM patients

          -  Right-handedness

          -  A regular menstrual cycle: 27-32 days

          -  Cramping pain during the menstrual period in the last 6 months , VAS â‰§ 7

          -  Abstinence for daily activities due to PDM

          -  Need analgesic or Physical therapy despite of no prominent effect

        Exclusion Criteria:

          -  History of head injury

          -  Pathological pituitary gland disease

          -  Organic pelvic disease, psychiatric disorder

          -  Pregnancy, childbirth

          -  A metal or pacemaker implant.

          -  Take hormone agents within 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Transcranial direct current stimulation</keyword>
  <keyword>Neuroplasticity</keyword>
  <keyword>Neuroimaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

